English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  [ 18 F]fluciclatide, a peptide ligand with high affinity for αvβ3/αvβ5 integrins, is a proposed biomarker of tumor angiogenesis. The study rationale was to perform a preliminary evaluation of the relationship between tumor [ 18 F]fluciclatide uptake and perfusion by [ 15 O]H 2 O PET.    Methods  Patients with non-small cell lung cancer and melanoma underwent dynamic imaging with arterial sampling following injection of [ 15 O]H 2 O and [ 18 F]fluciclatide. Quantification was performed using a one-tissue compartmental model for [ 15 O]H 2 O and a two-tissue model for [ 18 F]fluciclatide at volume-of-interest level, and SUV at voxel level.    Results  Tumor binding potential ( k  3 / k  4  ratio) of [ 18 F]fluciclatide tumor was 5.39 ± 1.46, consistent with previous studies in breast cancer metastases. Voxel-by-voxel maps of [ 18 F]fluciclatide delivery strongly correlated with [ 15 O]H 2 O-based perfusion ( p  < 10 −4  tumor, 1,794 ± 1,331 voxels). Interestingly, this correlation was lost when retention of [ 18 F]fluciclatide at late time-points was compared with perfusion ( p  > 0.15).    Conclusions  Our study suggests tumor [ 18 F]fluciclatide retention is unrelated to tumor perfusion, supporting use of late (60-min) imaging protocols in patients.    Electronic supplementary material  The online version of this article (doi:10.1186/s13550-014-0030-x) contains supplementary material, which is available to authorized users.

ejnmmi research

Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [18F]fluciclatide kinetics and [15O]H2O PET